Ray Cameron
- INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPDBy Andrea Rossi, Thys van der Molen, Ricardo del Olmo, Alberto Papi, Luis Wehbe, Matthew Quinn, Chengxing Lu, David Young, Ray Cameron, Enrica Bucchioni and Pablo AltmanArticle | Published in 2014 in European Respiratory JournalAndrea Rossi1Pulmonary Unit, University of Verona, Verona, ItalyThys van der Molen2University Medical Center Groningen, University of Groningen, Groningen, the NetherlandsRicardo del Olmo3Fundación CIDEA and Hospital Maria Ferrer, Buenos Aires, ArgentinaAlberto Papi4University of Ferrara, Ferrara, ItalyLuis Wehbe5Fundacion Enfisema, Buenos Aires, ArgentinaMatthew Quinn6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAChengxing Lu6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USADavid Young7Novartis Horsham Research Centre, Horsham, UKRay Cameron7Novartis Horsham Research Centre, Horsham, UKEnrica Bucchioni8Novartis Farma, Origgio, ItalyPablo Altman6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPDBy Andrea Rossi, Thys van der Molen, Ricardo del Olmo, Alberto Papi, Luis Wehbe, Matthew Quinn, Chengxing Lu, David Young, Ray Cameron, Enrica Bucchioni and Pablo AltmanAndrea Rossi1Pulmonary Unit, University of Verona, Verona, ItalyThys van der Molen2University Medical Center Groningen, University of Groningen, Groningen, the NetherlandsRicardo del Olmo3Fundación CIDEA and Hospital Maria Ferrer, Buenos Aires, ArgentinaAlberto Papi4University of Ferrara, Ferrara, ItalyLuis Wehbe5Fundacion Enfisema, Buenos Aires, ArgentinaMatthew Quinn6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAChengxing Lu6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USADavid Young7Novartis Horsham Research Centre, Horsham, UKRay Cameron7Novartis Horsham Research Centre, Horsham, UKEnrica Bucchioni8Novartis Farma, Origgio, ItalyPablo Altman6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms resultsBy Andrea Rossi, Thys Van der Molen, Ricardo Del Olmo, Alberto Papi, Luis Wehbe, Matthew Quinn, Chengxing Lu, David Young, Ray Cameron and Pablo AltmanAndrea Rossi1CardioThoracic Dept, Azienda Ospedaliera Universitaria Integrata, Verona, ItalyThys Van der Molen2University Medical Center Groningen, University of Groningen, Groningen, NetherlandsRicardo Del Olmo3Fundación CIDEA, Hospital Maria Ferrer, Buenos Aires, ArgentinaAlberto Papi4Department of Clinical and Experimental Medicine, University of Ferrara, Ferrara, ItalyLuis Wehbe5Fundacion Enfisema, Carlos M. Alvear 3345, Buenos Aires, ArgentinaMatthew Quinn6Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesChengxing Lu6Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDavid Young7Novartis Horsham Research Centre, Horsham, West Sussex, United KingdomRay Cameron7Novartis Horsham Research Centre, Horsham, West Sussex, United KingdomPablo Altman6Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.